Diversified portfolio with multiple late-stage programs
  • Masitinib is in Phase 2B/3 development phase in 8 indications simultaneously
  • Seven positive Phase 2B/3 read outs, in amyotrophic lateral sclerosis (ALS), progressive forms of multiple sclerosis (PPMS & nSPMS), indolent systemic mastocytosis (ISM), Severe Asthma uncontrolled by oral corticosteroids, Severe Asthma uncontrolled by inhaled corticosteroids, First Line Pancreatic Cancer with Pain and Alzheimer’s Disease.
High unmet medical need and strong market potential
  • The indications pursued are all high unmet medical needs
  • The indications pursued combined both blockbuster potential diseases or are orphan diseases
Unique mechanism of action
  • Lead compound: Masitinib, kinase inhibitor selectively targeting the innate immune system through mast cells and macrophages/microglia
  • New compound: AB8939, next generation, synthetic microtubule destabilizer able to overcome multidrug resistance
Strong IP position
  • IP 100% owned by AB Science
  • Patent protection until 2037 in ALS and up to 2036 in other indications